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Abstract: Elucidation of the cellular immunopathology and cytokine profile of psoriatic
arthritis (PsA), a chronic inflammatory disease associated with psoriasis, has resulted in the
development of a number of novel biologic therapies. Among these biologics, tumor necrosis
factor-alpha (TNF-α) inhibitors have been used successfully to treat patients suffering from
rheumatoid arthritis or psoriasis. The pivotal role of TNF-α in the pathogenesis and progression
of PsA suggested that anti-TNF-α agents could be effective in controlling PsA. The results
from two large, randomized, double-blind, placebo-controlled trials in patients with moderate
to severe PsA indicated that the anti-TNF- inhibitor, infliximab, can control both the joint and
skin manifestations of the disease. This review focuses on the clinical development of
infliximab as a treatment for PsA. The development of other anti-TNF-α biologics is also
discussed.
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Introduction
Psoriatic arthritis (PsA) is a progressive and often destructive form of inflammatory
arthritis that frequently occurs in psoriasis patients (Zachariae 2003). It is characterized
by moderate to severe psoriatic skin lesions with chronic joint pain, swelling, and
fatigue. In many cases, psoriasis symptoms may precede the arthritis component of
the disease by several years. PsA can be debilitating, culminating in severe, erosive
joint damage and functional impairment of individuals suffering from the disease.
Reduced qualities of life, increased risk of mortality, and premature death have all
been documented for patients with PsA (Wong et al 1997; Husted et al 2001; Sokoll
and Helliwell 2001). This review provides an update on the clinical development of
anti-tumor necrosis factor (TNF)-α agents like infliximab and other innovative
therapies that can be used to treat PsA.
Clinical presentation
The coexistence of inflammatory arthritis symptoms with psoriasis has been known
for many years but was not recognized as a clinical entity distinct from rheumatoid
arthritis (RA) and other arthropathies until pioneering observations by Wright (1959).
The condition was further codified in the 1960s and early 1970s (Blumberg et al
1964; Moll and Wright 1973b). Subsequent studies revealed that PsA shares a variety
of genetic, pathogenic, and clinical features with RA and other forms of inflammatory
arthritis. This has led to some confusion among clinicians when attempting to
distinguish among PsA, RA, and other forms of inflammatory arthritis. Nevertheless,
PsA can be distinguished from other arthropathies and, in particular RA, based on
several clinically distinct features of the disease.
First, approximately 80% of patients with RA are positive for the presence of
rheumatoid factor whereas 91%–94% of patients with PsA are negative for this factor
(Gladman 2005). Second, PsA and RA frequently differ in the extent of joint
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involvement and the pattern of inflamed joints. In general,
the involved joints in patients with PsA are fewer, less
inflamed, contain less fluid, and exhibit less tenderness
compared with those of RA patients (Gladman 1998).
Furthermore, inflammation tends to be more asymmetrical
in its distribution, at least in the early stages of PsA (Gladman
et al 1987, 2005). Dactylitis (digit inflammation), spondylitis
(spine involvement), sacroiliitis, and distal interphalangeal
joint involvement are also common in PsA but frequently
absent in RA (Gladman et al 1987; Fournie et al 1999).
Finally, patients with PsA virtually always have psoriatic
skin lesions whereas psoriasis occurs (by chance) in only
2%–3% of RA patients. Psoriatic nail lesions are very
common in PsA and help to distinguish between patients
who have PsA and those who have RA. Studies show that
nail lesions are present in approximately 87% of PsA patients
but occur in only 40%–46% of patients with uncomplicated
psoriasis (Gladman et al 1986). The presence of multiple
(20 or more) nail pit lesions has been used to distinguish
patients with PsA from those with RA and psoriasis
(Eastmond and Wright 1979).
In an attempt to refine and make the diagnostic criteria
for PsA more specific, several groups proposed combining
the unique clinical attributes of PsA with characteristic
radiological features commonly observed with the disease.
These include joint erosions, joint space narrowing, bony
proliferation including periarticular and shaft periostitis,
osteolysis (bone resorption) including “pencil in cup”
deformity and acro-osteolysis, ankylosis spur formation and
spondylitis (Moll and Wright 1973b; Gladman 1998;
Wassenberg et al 2001; Ory 2003). These unique
radiographic diagnostic criteria, in conjunction with
increased use of newer imaging techniques such as
ultrasonography and magnetic resonance imaging (MRI),
have helped to improve early detection and diagnosis of
PsA (Ory 2003; Ory et al 2005).
A classification scheme that recognizes five clinically
distinct patterns among patient with PsA was introduced in
1973 (Table 1) (Moll and Wright 1973b). These subtypes
include: 1) oligoarticular (<5 involved joints), often
asymmetric; 2) polyarticular, typically more symmetric; 3)
distal interphalangeal predominant; 4) spine predominant;
and 5) arthritis mutilans. In this first series of patients,
oligoarticular presentation was most common, but in all
subsequent large series, polyarticular presentation has been
most prevalent (Gladman et al 2005). Recognizing the need
for a classification system based on a more systematic
analysis of a large cohort of patients, Helliwell and Taylor
(2005) organized a multi-center study of approximately a
1000 patients, half with PsA and half “control” patients with
inflammatory arthritis, analyzed by history, physical exam,
laboratory and x-ray. The classification criteria being
developed will involve those aspects of the disease which
yield the greatest sensitivity and specificity for diagnosis
(Taylor 2006).
Etiology and pathogenesis of PsA
The prevalence of PsA and its rate of occurrence have been
difficult to estimate. This is largely due to the lack of a
universally-agreed upon diagnostic criteria and disease
classification scheme, coupled with a high frequency of
misdiagnosis (Helliwell and Taylor 2005). The rate of
occurrence of PsA among patients with psoriasis has also
been reported to vary widely, ranging from 6% to 39%
(Leonard et al 1978; Shbeeb et al 2000; Soderlin et al 2002;
Salonen 2003; Zachariae 2003; Gelfand et al 2005).
However, results from recent studies indicate that up to 30%
of patients with psoriasis develop PsA (Salonen 2003;
Zachariae 2003). PsA does not appear to be gender specific
and can develop at any age, although it is most common in
persons aged between 30 and 55 years (Espinoza et al 1992;
Helliwell and Taylor 2005).
The factors that contribute to the development and
pathogenesis of PsA are not completely understood. The
onset and development of PsA appear to involve a complex
interplay between genetics, environmental factors (eg,
physical trauma and infection), and the immune system.
Recent reports indicate that genetic factors may predispose
individuals to PsA (Gladman et al 1986, 1998, 1999, 2003).
In support of this, several population and twin studies
showed that the risk of developing PsA was elevated among
first degree and close relatives of PsA patients (Moll and
Wright 1973a; Swanbeck et al 1997). A strong association
Table 1 Clinical subtypes of PsA identified by Moll and Wright
(1973b)
Clinical subtypes  Disease features
Polyarticular RA-like (symmetrical) Nail lesions; symmetrical
pattern of joint involvement
Oligoarticular asymmetrical <5 joints involved; asymmetrical
joint involvement
Distal predominant pattern Distal interphalangeal joint
involvement prevalent
Spondylitis Spinal involvement is
predominant
Arthritis mutilans Severe joint destruction
Abbreviations: PsA, psoriatic arthritis; RA, rheumatoid arthritis.Therapeutics and Clinical Risk Management 2006:2(4) 391
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has also been demonstrated between PsA disease progression
and certain major histocompatibility complex (MHC) loci
(Armstrong et al 1983; Gladman et al 1986, 1998, 1999,
2003; Bowcock and Cookson 2004). A number of recent
studies identified a relationship between PsA and several
so-called psoriatic arthritis susceptibility genes (Gladman
2003; Karason et al 2003; Rahman et al 2003; Bowcock
2005). Finally, non-genetic factors, including bacterial
infections, various traumas (which lead to induction of
prolonged inflammatory reactions), and immune
dysregulation are also thought to contribute to the
development of PsA (Langevitz et al 1990; Gladman et al
2005).
Despite the lack of a clear understanding of the factors
that predispose individuals to PsA, identification of the
underlying immunological components of PsA has provided
insights into the pathogenesis and progression of the disease.
Activated T-cells, monocytes, and pro-inflammatory
cytokines, most notably TNF-α, have all been shown to play
pivotal roles in the pathogenesis of both the joint and
psoriatic components of PsA (Figure 1) (Gladman 1993;
Costello et al 1999; Mease 2003, 2004b). It is generally
agreed that T-cell activation, followed by a vigorous Th1
cytokine response, is responsible for the inflammatory
reactions that characterize the skin and joint lesions observed
in patients with PsA (Ritchlin et al 1998; Veale et al 2005).
The key mediators of these inflammatory responses are the
pro-inflammatory cytokines, TNF-α, interleukin (IL)-1, IL-
6 and IL-8 (for a review see Mease and Goffe 2005).
Elevated levels of these cytokines are thought to induce the
proliferation and activation of synovial and epidermal
fibroblasts, which results in the joint fibrosis that is
characteristic of chronic PsA disease (Espinoza, Aguilar, et
al 1994; Espinoza, Espinoza, et al 1994). Pro-inflammatory
cytokines can also stimulate the proliferation of skin
keratinocytes, which leads to further inflammation,
induration, and psoriatic plaque formation (Giustizieri
et al 2001). Finally, these cytokines upregulate the
expression of endothelial and dendritic cell adhesion
molecules, intercellular adhesion molecules-1 (ICAM-
1), vascular cell adhesion molecules-1 (VCAM-1), and
E-selectin, which promote the recruitment and access of
activated T-cells to afflicted joints. This results in the
release of additional TNF-α, which stimulates
inflammation, interferes with bone formation, hinders
proteoglycan synthesis and promotes joint destruction
(Saklatvala 1986; Veale et al 1993, 1995; Terajima et al
1998).
In addition to their roles as inflammatory response
regulators, IL-1 and TNF-α recently were found to play
central roles in bone metabolism (Bertolini et al 1986;
Nakashima et al 2003). These cytokines are thought to
stimulate bone resorption (osteoclastogenesis) by
upregulating the synthesis of osteoprotegerin ligand, a newly
identified member of the TNF receptor family that is
expressed by activated T-cells (Lacey et al 1998; Burgess
et al 1999). The finding that erosive joint disease in PsA is
associated with increased osteoclast precursors in the
peripheral circulation suggests that the effects of IL-1 and
TNF-α on bone metabolism likely contribute to the PsA-
induced joint disease (Saklatvala 1986; Ritchlin et al 2003).
Figure 1 The inflammatory response cascade induced by tumor necrosis factor-
α (TNF-α) manifesting in joint destruction. Copyright © 2005. Reproduced from
Mease PJ, Goffe BS, Metz J, et al. 2000. Etanercept in the treatment of psoriatic
arthritis and psoriasis: a randomised trial. Lancet, 356:385-90. TNF-α binding
stimulates mononuclear phagocytes to secrete the pro-inflammatory cytokines
interleukin (IL)-1, IL-6, and granulocyte macrophage–colony stimulating factor
(GM-CSF). These cytokines promote recruitment of T-cells into afflicted joints
and also stimulate proliferation of osteoclasts, synovial fibroblasts and
chondrocytes at these sites. The resultant inflammatory responses, coupled with
release of metalloproteinases and other effector molecules by activated cells,
results in joint destruction.Therapeutics and Clinical Risk Management 2006:2(4) 392
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IL-1 and TNF-α also stimulate monocytes and dendritic cells
to overproduce metalloproteinases and prostaglandin E2,
which mediate cartilage and collagen erosion in affected
joints (Dayer et al 1985; Ritchlin et al 2003).
Over the past two decades, it has become increasingly
apparent that PsA can be a serious disease with substantial
morbidity and mortality when not diagnosed early or treated
properly. Historically, PsA treatment has been empirically
determined, drawing on therapies that have been used to
treat either RA, psoriasis or both (Gladman 2003; Pipitone
et al 2003). With this in mind, the type and course of
treatment for patients with PsA usually depend upon the
extent and severity of both skin and joint manifestations.
Because a majority of PsA patients typically have psoriatic
skin involvement, in addition to arthritis, the PsA therapy
that is typically employed should attempt to target both the
skin and joint disease.
Treatment
The medications traditionally used to treat PsA have
included non-steroidal anti-inflammatory drugs (NSAIDs)
and disease-modifying anti-rheumatic drugs (DMARDs),
such as methotrexate, sulphasalazine and leflunomide,
sometimes in combination with topical and light therapies
for skin manifestations (Gladman 2003, 2005; Pipitone et
al 2003; Nash and Clegg 2005). NSAID treatment helps to
control arthritis pain and may work for mild inflammation
in patients with PsA (Gladman 2003, 2005; Pipitone et al
2003; Nash and Clegg 2005). Mild skin involvement has
been typically treated with topical medications including
corticosteroid creams, tar shampoos, vitamin D creams and
ultraviolet (UV) irradiation (Gladman 2003; Lebwohl et al
2005). More severe skin disease, which may be refractory
to topical drug treatment, can be treated with psoralen with
UVA irradiation, cyclosporine, and methotrexate (MTX)
(Brockbank and Gladman 2002; Gladman 2003; Pipitone
et al 2003). In cases where both skin and joint involvement
are severe, systemic therapies using the DMARD agents,
MTX, cyclosporine, and sulfasalazine have been
traditionally used to treat PsA (Marguerie et al 2002). A
thorough review of these traditional therapies is beyond the
scope of this paper; detailed reviews can be found elsewhere
(Nash and Clegg 2005; Lebwohl et al 2005).
Although NSAIDs and DMARDs provide some patients
with substantial relief from both the dermatologic and
arthritic symptoms of PsA, none of these agents has been
successfully shown to control or hinder progression of the
disease, as measured radiographically and there may be a
high discontinuation rate due to lack of efficacy or adverse
effects (Abu-Shakra et al 1995; Mader et al 1995; Rahman
et al 1998; Nash and Clegg 2005). Over the past few years,
the armamentarium of medications used to treat PsA has
been greatly expanded to include biological agents, and
several newer treatments exhibit improved efficacy over
conventional therapies (Pipitone et al 2003; Gladman 2005;
Mease and Antoni 2005).
Anti-TNF-α agents
Because TNF-α mediates multiple biological processes in
the pathogenesis of PsA (Figure 1), a reduction in TNF-α
levels was postulated to improve clinical outcomes in
patients suffering from PsA. Several anti-TNF-α
medications approved for treating and controlling RA were
studied in patients with PsA and found to manage effectively
both the psoriatic and arthritic manifestations of the disease.
This resulted in the clinical development of a variety of TNF-
α inhibitors, including infliximab, etanercept, adalimumab,
and others, to treat PsA (Mease and Antoni 2005).
Infliximab for the treatment of PsA
Infliximab is a chimeric, human-mouse IgG1 monoclonal
antibody that specifically targets and neutralizes soluble and
membrane-bound TNF-α. It is approved for a variety of
autoimmune diseases, including Crohn’s disease and
ulcerative colitis (the only biologic approved for these
indications) and moderate to severe RA (when used in
combination with MTX). The drug was approved by the
European Union (EU) in 2004 for use in combination with
MTX to treat active and progressive PsA in patients who
have responded inadequately to DMARDs. Partly related
to dermatologist’s concerns about chronic methotrexate use
in psoriasis patients, the inclusion criteria for the pivotal
clinical trials made MTX use optional. Consequently, when
infliximab was approved by the FDA for the treatment of
PsA in late 2005, it was approved for monotherapy. In 2005,
infliximab was approved by the EU for the treatment of
moderate to severe plaque psoriasis.
Clinical development of infliximab for PsA was
indicated following an open-label, compassionate-use,
clinical trial conducted on 10 DMARD-refractory PsA
patients. The results from this study showed that infliximab
was effective, safe and well tolerated for treating both the
psoriatic and joint components of PsA (Antoni et al 2002).
Positive results from a second clinical study that evaluated
the safety and efficacy of infliximab on patients with
spondyloarthropathy, which also included patients with PsA,Therapeutics and Clinical Risk Management 2006:2(4) 393
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prompted late-stage clinical development of infliximab for
PsA (Van den Bosch et al 2000). Two randomized, double-
blind, placebo-controlled trials—one designated IMPACT
(Infliximab Multinational Psoriatic Arthritis Controlled
Trial) and a second called IMPACT II—were conducted to
determine whether infliximab could be used to treat PsA
(Antoni, Krueger, et al 2005; Antoni, Kavanaugh, et al
2005).
The IMPACT trial included 104 patients with PsA who
were seronegative for rheumatoid factor, had at least five
tender and five swollen joints, and were refractory to therapy
with ≥1 DMARD (Antoni, Kavanaugh, et al 2005). Patients
were required to have negative results for active or latent
tuberculosis by purified protein derivative skin test and chest
radiography. Patients were allowed to receive concomitant
therapy with MTX, leflunomide, sulfasalazine,
hydroxychloroquine, intramuscular gold, penicillamine, or
azathioprine and stayed on baseline dosages of these
medications throughout the study. Patients were randomized
into an infliximab treatment group (52 patients at 5 mg/kg/
infusion) or placebo (52 patients) for four infusions that
were administered at 0, 2, 6, and 14 weeks. After week 16,
patients initially assigned to receive placebo crossed over
to receive infliximab 5 mg/kg every 8 weeks through week
50, while patients initially randomized to infliximab
continued to receive active treatment at the same dose
through week 50. The primary efficacy outcome of the
randomized, double-blind portion of the study was
achievement of the American College of Rheumatology
criteria for 20% improvement in rheumatoid arthritis
(ACR20) at 16 weeks. Main secondary endpoints included
an assessment of skin involvement using the Psoriasis Area
and Severity Index (PASI), and the proportion of patients
who achieved ACR50 and ACR70 and the Psoriatic Arthritis
Response Criteria (PsARC).
The proportion of infliximab-treated patients who
achieved ACR20 at 16 weeks was 65%, which was
significantly higher (p<0.001) than the response of the
placebo group (10%) (Antoni, Kavanaugh, et al 2005).
Moreover, 46% of infliximab-treated patients achieved an
ACR50 and 29% achieved an ACR70 response, whereas
none of the placebo-treated patients achieved either of these
two endpoints (p<0.001). At the 16-week evaluation, 75%
of infliximab-treated patients improved according to
PsARC, compared with only 21% of placebo-treated patients
(p<0.001). The percentage improvement in ACR20 achieved
by infliximab-treated patients at week 16 was sustained
through week 50 of the study (Figure 2). Moreover,
crossover patients from the placebo group, who received
infliximab therapy after week 16, achieved ACR20 response
rates at week 50 that were comparable with those exhibited
by patients who were initially placed in the infliximab
treatment group. It is important to note that, at week 16, the
concomitant use of DMARDs (primarily MTX) had no
significant effect on the ACR20 response rate in either the
infliximab-treated or placebo groups. For example, 62.5%
of infliximab patients also receiving MTX achieved an
ACR20 response rate at 16 weeks, as did 68% of infliximab
patients not receiving MTX and 74% of patients not
receiving DMARD therapy.
Skin responses were measured in 39 patients (21 patients
randomized to infliximab and 18 randomized to placebo),
all of whom had PASI scores of ≥2.5 at baseline (Antoni,
Kavanaugh, et al 2005). Among patients with baseline PASI
scores of ≥2.5, 68% of infliximab-treated patients showed
an improvement of ≥75% in PASI score at week 16 as
compared with none of the patients in the placebo group
(p<0.001; Figure 3). After crossing over to infliximab
therapy, patients initially assigned to the placebo group
experienced improvements in skin response that were very
similar to those exhibited by patients in the infliximab
treatment group. Both groups were able to maintain the skin
responses until week 50 of the study.
As part of the IMPACT study, hand and feet radiographs
were obtained for 72/104 patients at 0 and 50 weeks
(Kavanaugh, Antoni, Gladman, et al 2006). The missing
patients consisted of 10 patients who discontinued the study,
8 patients who did not have any radiographic films, 3 patients
who did not have a baseline film or who had an unevaluable
film at baseline, and 11 patients who did not have
radiographic films at 50 weeks. Total radiographic scores
for these patients were determined using the PsA-modified
van der Heijde-Sharp (vdH-S) method (Van der Heijde et al
2005). At baseline, the estimated mean annual rate of
progression of PsA was 5.8 modified-vdH-S points per year
for patients in both the placebo and treatment groups. Mean
changes from baseline to week 50 in the total modified vdH-
S score were –1.95 ± 0.50 for the placebo/infliximab
treatment group and –1.50 ± 0.50 for the infliximab group.
At week 50, 85% of patients in the placebo/infliximab
group and 84% of patients in the infliximab group had
no worsening in total modified vdH-S scores. These
results suggest that either continued or delayed treatment
with infliximab had marked inhibitory effects on
radiographic PsA disease progression; however, if
radiographic progression was not linear in this group ofTherapeutics and Clinical Risk Management 2006:2(4) 394
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patients with PsA, it is possible that the reduced
radiographic change may have been independent of
treatment with infliximab.
Infliximab treatment was generally well tolerated with
a discontinuation rate of only 13% over the 50 weeks of the
study. There were no significant differences in the numbers
or types of adverse events reported in infliximab treatment
or placebo groups. Only two patients reported serious
adverse events (one in the placebo group and one in the
infliximab group). No patients experienced opportunistic
infection, including tuberculosis, nor were there any reports
of autoimmune, cytopenic or neurologic events (Antoni,
Kavanaugh, et al 2005).
A second, larger randomized, double-blind IMPACT II
trial was initiated to confirm the efficacy and safety of
infliximab observed in the original IMPACT study (Antoni,
Krueger, et al 2005). Patients were required to be
prescreened for tuberculosis (TB) as in the original IMPACT
study. In this trial, 200 patients with active PsA who were
refractory to previous treatment were randomized to
infusions of infliximab 5 mg/kg or placebo at weeks 0, 2, 6,
14, and 22. The primary measure of clinical response was
the percentage of patients achieving ACR20, and secondary
endpoints included PsARC, PASI, dactylitis and
enthesopathy assessments. At baseline, the percentages of
patients with 1 or more dactylitis digits or with enthesopathy
were 41% and 35%, respectively, for placebo-treated
patients and 40% and 42%, respectively, for infliximab-
treated patients. At week 14, 58% of the patients who
received infliximab and 11% receiving placebo achieved
an ACR20 response (p<0.001). Additionally, 77% of
infliximab-treated patients and 27% of placebo-treated
achieved PsARC (p<0.001). Furthermore, at week 14, 64%
of patients who received infliximab had at least a 75%
improvement in PASI compared with only 2% of the patients
receiving placebo (p<0.001). Fewer infliximab-treated
patients compared with placebo had dactylitis at both week
14 (18% vs 30%; p=0.025) and week 24 (12% vs 34%,
p<0.001). Also, fewer patients in the infliximab-treated
group as compared with placebo-treated patients had active
enthesopathy at week 14 (22% vs 34%, p=0.016) and week
24 (20% vs 37%, p=0.002). All of the therapeutic effects
Figure 2 Percentages of patients achieving improvement by the American College of Rheumatology 20% (ACR20) criteria for improvement in rheumatoid arthritis
through week 50. Results from the Phase III, IMPACT trial that assessed the effectiveness of infliximab for treating psoriatic arthritis. Copyright © 2005. Reproduced
with permission from Antoni CE, Kavanaugh A, Kirkham B, et al. 2005. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of
psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum, 52:1227-36. Arrows indicate weeks at which
infusions were administered: open arrows denote placebo (Pbo) infusions, and solid arrows denote infusions of infliximab (Inf) 5 mg/kg.Therapeutics and Clinical Risk Management 2006:2(4) 395
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exhibited by infliximab were observed through the last
evaluation that took place at week 24. Infliximab was
generally well tolerated, with a similar incidence of adverse
effects in the infliximab-treated and placebo groups. A
radiographic analysis similar to that conducted in the first
IMPACT study was also conducted for IMPACT II (Van
der Heijde et al 2005). The results from this study
corroborated the results obtained in the first IMPACT
study, which suggested that treatment with infliximab had
marked inhibitory effects on radiographic PsA disease
progression.
The effects of infliximab on health-related quality of
life (HRQoL) in patients with PsA who were enrolled in the
IMPACT II study were recently reported (Kavanaugh,
Antoni, Krueger, et al 2006). HRQoL was assessed using
the 36-item Short Form Health Survey (SF-36) and
functional disability was assessed using the Health
Assessment Questionnaire (HAQ). At week 14, the mean
percentage improvement from baseline in HAQ scores was
48.6% for infliximab-treated patients, compared with a
worsening of 18.4% in the placebo-treated patients
(p<0.001). Improvement in all eight scales of the SF-36 were
greater than those in the placebo group at week 14 (p<0.001),
with these benefits sustained through week 24.
Infliximab for the treatment of psoriasis
A role for TNF-α in the pathogenesis of psoriasis, along
with results from the two IMPACT studies, suggested that
infliximab may also provide therapeutic benefits for patients
suffering from severe psoriasis. This prompted the initiation
of two multicenter, randomized, double-blind and placebo-
controlled Phase III studies to assess the effects of infliximab
on patients with severe plaque psoriasis. The first of these
studies, called SPIRIT (Study of Psoriasis with Infliximab
[REMICADE] Induction Therapy) (Gottlieb et al 2004) was
conducted in the US whereas the second trial, designated
EXPRESS (European Infliximab for Psoriasis
[REMICADE] Efficacy and Safety Study) (Reich et al
2005), was conducted in Europe.
The SPIRIT trial evaluated the efficacy, safety, and
tolerability of infliximab therapy in 249 patients with severe
plaque psoriasis who had previously received long-wave
ultraviolet-A light (PUVA) or systemic therapy for psoriasis
(Gottlieb et al 2004). These patients were randomly assigned
to receive intravenous infusions of either 3.0 mg/kg (99
patients) or 5.0 mg/kg (99 patients) infliximab or placebo
(51 patients) at 0, 2, and 6 weeks. The primary endpoint of
the study was the proportion of patients who achieved at
least 75% improvement in PASI scores (PASI 75) from
Figure 3 Psoriasis Area and Severity Index (PASI) scores (mean and SD) at baseline, week 16, and week 50 in patients who had a PASI score of ≥2.5 at baseline.
Results from the Phase III, IMPACT trial that assessed the effectiveness of infliximab for treating PsA. Copyright © 2005. Reproduced with permission from Antoni
CE, Kavanaugh A, Kirkham B, et al. 2005. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the
infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum, 52:1227-36.Therapeutics and Clinical Risk Management 2006:2(4) 396
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baseline at week 10. At week 26, patients with a Physician
Global Assessment score that indicated moderate or severe
disease were eligible for a single intravenous infusion of
their assigned treatment regimen to assess the safety of
retreatment after a 20-week treatment-free interval.
Approximately two-thirds of the patients had received prior
phototherapy and 90.8% had received prior therapy with
systemic agents. At week 10, 72% of patients treated with
infliximab (3 mg/kg ) and 88% of patients treated with
infliximab (5 mg/kg) achieved 75% or greater improvement
from baseline PASI 75 scores as compared with only 6% of
patients treated with placebo (p<0.001). Nearly 50% of the
patients treated with infliximab 5mg/kg achieved PASI 75
scores as early as week 4. Moreover, 58% of the patients
experienced PASI 90 (almost complete clearance of lesions)
by week 10. At week 26, 114 patients were retreated with
their initial dose of study medication. Four weeks after
retreatment, the percentages of patients in the 3 mg/kg, 5 mg/
kg, and placebo groups who achieved a Physician’s Global
Assessment (PGA) of mild, minimal, or clear (PGA <3) were
38%, 64%, and 18%, respectively. There was no significant
difference in the number of adverse events reported by
patients in the treatment or placebo groups, and infliximab
was generally well tolerated in this study. The retreatment
infusion was well tolerated with no hypersensitivity
reactions reported.
The EXPRESS study evaluated the effects of infliximab
on 378 patients with moderate to severe plaque psoriasis
(Reich et al 2005). These patients were randomized into
two groups that received infusions of either infliximab 5 mg/
kg or placebo at weeks 0, 2, and 6, and then every 8 weeks
up to week 46. At week 24, placebo-treated patients were
permitted to crossover to infliximab treatment. Skin signs
of psoriasis were assessed using PASI scores, and the
primary endpoint in the study was the proportion of patients
who achieved at least 75% improvement in PASI (PASI 75)
from baseline to week 10. At week 10, 80% of patients
treated with infliximab achieved at least 75% improvement
from baseline PASI as compared with only 3% of patients
in the placebo group (p<0.0001). Moreover, 57% of
infliximab-treated patients, as compared with only 1% of
patients in the placebo group, achieved 90% improvement
in PASI. PASI 75 scores were maintained at week 24 by
82% of infliximab-treated patients and 4% of patients who
received placebo (p<0.0001). At week 50, 61% of infliximab
patients were able to sustain PASI 75 levels and 45%
achieved PASI 90 scores. A pre-specified subanalysis of
responders showed that 89% of the patients who achieved a
PASI 75 score at week 10 maintained this level of response
at 6 months and 65% sustained this response at 1 year.
Similar to the results from the SPIRIT study, infliximab was
generally well tolerated.
The effects of treatment with infliximab on HRQoL in
patients enrolled in the EXPRESS study was recently
published (Reich et al 2006). At week 10, patients treated
with infliximab had significantly greater improvement in
Dermatology Life Quality Index scores than placebo-treated
patients (p<0.001). Significant improvement was also
reported for all eight subscales of the SF-36 for infliximab-
versus placebo-treated patients (p<0.001). The significant
improvement in HRQoL persisted at week 24, and
substantial benefit still remained at week 50.
Dosing of infliximab
For psoriatic arthritis, the recommended dosing of infliximab
in the US and the EU is 5 mg/kg given as an intravenous
infusion (Remicade package insert 2006a, 2006b). This is
followed with similar doses at 2 and 6 weeks after the first
infusion, then every 8 weeks thereafter. Infliximab can be
used with or without MTX.
For psoriasis, the recommended dosing of infliximab in
the EU is 5 mg/kg given as an intravenous infusion over a
2-hour period, followed by additional 5 mg/kg infusion
doses at 2 and 6 weeks after the first infusion, then every 8
weeks thereafter (Remicade package insert 2006a). If a
patient shows no response after 14 weeks (ie, after 4 doses),
no additional treatment with infliximab should be given.
Other TNF-α agents
Etanercept
Etanercept is a fully human soluble TNF receptor-IgG fusion
protein that binds and inactivates soluble and cell-bound
TNF-α and lymphotoxin (TNF-α) (Mease et al 2004). It is
approved for use in the US and Europe to treat patients with
PsA and also approved to treat psoriasis patients who are
candidates for phototherapy or systemic DMARD therapy.
Unlike infliximab, which is administered intravenously,
etanercept is given subcutaneously as a 25 mg twice weekly
or 50 mg weekly treatment regimen. The efficacy of
etanercept in PsA was shown in 2 randomized, double-blind,
placebo-controlled clinical trials (Mease et al 2000, 2004).
Adalimumab
Adalimumab, a fully human anti-TNF monoclonal antibody,
is currently approved for the treatment of RA and PsA
(Keystone et al 2004). In addition to being fully humanized,Therapeutics and Clinical Risk Management 2006:2(4) 397
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which reduces the incidence of induction of neutralizing
immune responses, it has the advantage of being
administered subcutaneously at biweekly intervals
(Gladman 2005). The effectiveness of adalimumab for
treating PsA was suggested based on results from a small
open-label clinical trial (Ritchlin et al 2004) and recently
verified in a larger, randomized, double-blind, placebo-
controlled study (ADEPT) (Mease, Gladman, Ritchlin,
2005).
Safety profiles of TNF-α antagonists
Infliximab and the other TNF-α inhibitors are generally well
tolerated by patients. Some of the more frequently reported
side effects of all of these agents include: 1) increased risk
of infection, particularly mycobacterial infections, 2)
induction of anti-nuclear antibodies, 3) possible increased
cancer risk, and 4) infusion/injection site hypersensitivity
reactions (Braun and Sieper 2003). Injection site reactions
with etanercept and adalimumab generally are mild and
transient. Infusion reactions with infliximab occur
infrequently and can generally be managed with slowing
the infusion rate and/or medical treatment (Terajima et al
1998; Braun and Sieper 2003; Cheifetz et al 2003). It has
been shown that patients with RA have a higher risk of
lymphoma and leukemia than the general population;
however, the risk of lymphoma and leukemia during
treatment with different TNF-α antagonists is not
significantly different than for RA patients in general
(Askling, Fored, Baecklund, et al 2005). A similar study of
the risk of solid cancers reported that RA patients have a
70% increased risk for non-melanoma skin cancer, which
was increased somewhat during treatment with TNF-α
antagonists (standardized incidence ratio = 3.6) (Askling,
Fored, Brandt, et al 2005). Long-term studies will be
required to characterize further the safety risks associated
with TNF-α antagonists.
Switching among TNF-α antagonists
Although it has not been studied in patients with PsA, it has
been shown in patients with RA and spondyloarthropathy
that a reasonable approach to use when one TNF-α
antagonist loses its effectiveness is to switch to a different
agent in the same class. Observational studies have shown
that a substantial number of patients who experience adverse
events or lack of effectiveness with one TNF-α antagonist
may benefit from a switch to a different TNF-α antagonist
(Delaunay et al 2005; Wick et al 2005; Gomez-Reino and
Carmona 2006).
New PsA treatments: T-cell-directed
agents
Other biological therapies proposed for PsA treatment
attempt to interfere with T-cell recruitment and activation,
activities which are thought to play a role in the pathogenesis
of PsA. Although the exact role of T-cells in PsA is poorly
understood, their contribution to the disease is based on the
finding that T-cells are routinely present in high numbers in
the inflammatory infiltrate found in PsA-associated skin
lesions and afflicted joints. Two new drugs, efalizumab and
alefacept that interfere with T-cell function and effector cell
interactions have been approved for psoriasis and have been
preliminarily investigated for treatment of PsA.
Efalizumab is a humanized IgG1 monoclonal antibody
that is thought to act by inhibiting T-cell recruitment and
activation at sites of chronic inflammation. Efalizumab is
effective in treating psoriasis and has been approved for
this use in the US (Gordon et al 2003; Lebwohl et al 2003).
Results from a recent clinical phase 2 study in PsA did not
show statistically significant superiority in the efalizumab
arm of the study (Mease 2004a).
Alefacept is a fully human, anti-T-cell receptor fusion
protein that is thought to reduce inflammatory reactions by
preventing T-cell activation and proliferation and inducing
selective T-cell apoptosis (Ellis and Krueger 2001).
Alefacept has been approved for use in psoriasis and has
been shown to be effective in treating PsA in preliminary
clinical studies (Korman and Moul 2005; Mease, Gladman,
Keystone 2005, 2006). Although alefacept has shown a
statistically significant improvement over placebo, the
magnitude of the effect was modest.
Conclusions
Although the factors responsible for development and
progression of PsA are still not completely understood, new
insights into the underlying immunological mechanisms of
the disease have resulted in the development of novel
therapies. These include the widely-used anti-TNF-α
antagonists and the newer T-cell directed agents. Both new
drug classes have the potential for superior efficacy and
improved tolerability profiles when compared with
traditional PsA treatments. Furthermore, the biologics may
possibly have a better overall safety profile than
conventional treatments. Moreover, unlike older,
conventional PsA treatments, these new agents may hinder
or inhibit the progression of PsA and thus prevent the erosive
joint damage that interferes with the quality of life of manyTherapeutics and Clinical Risk Management 2006:2(4) 398
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PsA patients. Thus, infliximab, as the first FDA-approved
TNF-α monoclonal antibody, may provide a significant
advance in treatment for some patients with PsA.
References
Abu-Shakra M, Gladman DD, Thorne JC, et al. 1995. Longterm
methotrexate therapy in psoriatic arthritis: clinical and radiological
outcome. J Rheumatol, 22:241-5.
Antoni C, Dechant C, Hanns-Martin Lorenz PD, et al. 2002. Open-label
study of infliximab treatment for psoriatic arthritis: clinical and
magnetic resonance imaging measurements of reduction of
inflammation. Arthritis Rheum, 47:506-12.
Antoni C, Krueger GG, de Vlam K, et al. 2005. Infliximab improves signs
and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
Ann Rheum Dis, 64:1150-7.
Antoni CE, Kavanaugh A, Kirkham B, et al. 2005. Sustained benefits of
infliximab therapy for dermatologic and articular manifestations of
psoriatic arthritis: results from the infliximab multinational psoriatic
arthritis controlled trial (IMPACT). Arthritis Rheum, 52:1227-36.
Armstrong RD, Panayi GS, Welsh KI. 1983. Histocompatibility antigens
in psoriasis, psoriatic arthropathy, and ankylosing spondylitis. Ann
Rheum Dis, 42:142-6.
Askling J, Fored CM, Baecklund E, et al. 2005. Haematopoietic
malignancies in rheumatoid arthritis: lymphoma risk and
characteristics after exposure to tumour necrosis factor antagonists.
Ann Rheum Dis, 64:1414-20.
Askling J, Fored CM, Brandt L, et al. 2005. Risks of solid cancers in
patients with rheumatoid arthritis and after treatment with tumour
necrosis factor antagonists. Ann Rheum Dis, 64:1421-6.
Bertolini DR, Nedwin GE, Bringman TS, et al. 1986. Stimulation of bone
resorption and inhibition of bone formation in vitro by human tumour
necrosis factors. Nature, 319:516-18.
Blumberg BS, Bunim JJ, Calkins E, et al. 1964. ARA nomenclature and
classification of arthritis and rheumatism. Arthritis Rheum, 7:93-7.
Bowcock AM. 2005. Understanding the pathogenesis of psoriasis, psoriatic
arthritis, and autoimmunity via a fusion of molecular genetics and
immunology. Immunol Res, 32:45-56.
Bowcock AM, Cookson WO. 2004. The genetics of psoriasis, psoriatic
arthritis and atopic dermatitis. Hum Mol Genet, 13:R43-55.
Braun J, Sieper J. 2003. Role of novel biological therapies in psoriatic
arthritis: effects on joints and skin. BioDrugs, 17:187-99.
Brockbank J, Gladman D. 2002. Diagnosis and management of psoriatic
arthritis. Drugs, 62:2447-57.
Burgess TL, Qian Y, Kaufman S, et al. 1999. The ligand for osteoprotegerin
(OPGL) directly activates mature osteoclasts. J Cell Biol, 145:527-38.
Cheifetz A, Smedley M, Martin S, et al. 2003. The incidence and
management of infusion reactions to infliximab: a large center
experience. Am J Gastroenterol, 98:1315-24.
Costello P, Bresnihan B, O’Farrelly C, et al. 1999. Predominance of CD8+
T lymphocytes in psoriatic arthritis. J Rheumatol, 26:1117-24.
Dayer JM, Beutler B, Cerami A. 1985. Cachectin/tumor necrosis factor
stimulates collagenase and prostaglandin E2 production by human
synovial cells and dermal fibroblasts. J Exp Med, 162:2163-8.
Delaunay C, Farrenq V, Marini-Portugal A, et al. 2005. Infliximab to
etanercept switch in patients with spondyloarthropathies and psoriatic
arthritis: preliminary data. J Rheumatol, 32:2183-5.
Eastmond CJ, Wright V. 1979. The nail dystrophy of psoriatic arthritis.
Ann Rheum Dis, 38:226-8.
Ellis CN, Krueger GG. 2001. Treatment of chronic plaque psoriasis by
selective targeting of memory effector T lymphocytes. N Engl J Med,
345:248-55.
Espinoza LR, Aguilar JL, Espinoza CG, et al. 1994. Fibroblast function in
psoriatic arthritis. I. Alteration of cell kinetics and growth factor
responses. J Rheumatol, 21:1502-6.
Espinoza LR, Cuellar ML, Silveira LH. 1992. Psoriatic arthritis. Curr
Opin Rheumatol, 4:470-8.
Espinoza LR, Espinoza CG, Cuellar ML, et al. 1994. Fibroblast function
in psoriatic arthritis. II. Increased expression of beta platelet derived
growth factor receptors and increased production of growth factor
and cytokines. J Rheumatol, 21:1507-11.
Fournie B, Crognier L, Arnaud C, et al. 1999. Proposed classification
criteria of psoriatic arthritis. A preliminary study in 260 patients. Rev
Rhum Engl Ed, 66:446-56.
Gelfand JM, Gladman DD, Mease PJ, et al. 2005. Epidemiology of
psoriatic arthritis in the population of the United States. J Am Acad
Dermatol, 53:573.
Giustizieri ML, Mascia F, Frezzolini A, et al. 2001. Keratinocytes from
patients with atopic dermatitis and psoriasis show a distinct chemokine
production profile in response to T cell-derived cytokines. J Allergy
Clin Immunol, 107:871-7.
Gladman DD. 1993. Toward unraveling the mystery of psoriatic arthritis.
Arthritis Rheum, 36:881-4.
Gladman DD. 1998. Psoriatic arthritis. Rheum Dis Clin North Am, 24:829-
44, x.
Gladman DD. 2003. Effectiveness of psoriatic arthritis therapies. Semin
Arthritis Rheum, 33:29-37.
Gladman DD. 2005. Traditional and newer therapeutic options for psoriatic
arthritis: an evidence-based review. Drugs, 65:1223-38.
Gladman DD, Anhorn KA, Schachter RK, et al. 1986. HLA antigens in
psoriatic arthritis. J Rheumatol, 13:586-92.
Gladman DD, Antoni C, Mease P, et al. 2005. Psoriatic arthritis:
epidemiology, clinical features, course, and outcome. Ann Rheum Dis,
64(Suppl 2):ii14-7.
Gladman DD, Cheung C, Ng CM, et al. 1999. HLA-C locus alleles in
patients with psoriatic arthritis (PsA). Hum Immunol, 60:259-61.
Gladman DD, Farewell VT, Kopciuk KA, et al. 1998. HLA markers and
progression in psoriatic arthritis. J Rheumatol, 25:730-3.
Gladman DD, Farewell VT, Pellett F, et al. 2003. HLA is a candidate
region for psoriatic arthritis. evidence for excessive HLA sharing in
sibling pairs. Hum Immunol, 64:887-9.
Gladman DD, Shuckett R, Russell ML, et al. 1987. Psoriatic arthritis
(PSA)—an analysis of 220 patients. Q J Med, 62:127-41.
Gomez-Reino JJ, Carmona L. 2006. Switching TNF antagonists in patients
with chronic arthritis: an observational study of 488 patients over a
four-year period. Arthritis Res Ther, 8:R29.
Gordon KB, Papp KA, Hamilton TK, et al. 2003. Efalizumab for patients
with moderate to severe plaque psoriasis: a randomized controlled
trial. JAMA, 290:3073-80.
Gottlieb AB, Evans R, Li S, et al. 2004. Infliximab induction therapy for
patients with severe plaque-type psoriasis: a randomized, double-blind,
placebo-controlled trial. J Am Acad Dermatol, 51:534-42.
Helliwell PS, Taylor WJ. 2005. Classification and diagnostic criteria for
psoriatic arthritis. Ann Rheum Dis, 64(Suppl 2):ii3-8.
Husted JA, Gladman DD, Farewell VT, et al. 2001. Health-related quality
of life of patients with psoriatic arthritis: a comparison with patients
with rheumatoid arthritis. Arthritis Rheum, 45:151-8.
Karason A, Gudjonsson JE, Upmanyu R, et al. 2003. A susceptibility gene
for psoriatic arthritis maps to chromosome 16q: evidence for
imprinting. Am J Hum Genet, 72:125-31.
Kavanaugh A, Antoni C, Krueger GG, et al. 2006. Infliximab improves
health related quality of life and physical function in patients with
psoriatic arthritis. Ann Rheum Dis, 65:471-7.
Kavanaugh A, Antoni CE, Gladman DD, et al. 2006. The Infliximab
Multinational Psoriatic Arthritis Controlled Trial (IMPACT): Results
of radiographic analyses after 1 year. Ann Rheum Dis, 65:1038-43.
Keystone EC, Kavanaugh AF, Sharp JT, et al. 2004. Radiographic, clinical,
and functional outcomes of treatment with adalimumab (a human anti-
tumor necrosis factor monoclonal antibody) in patients with active
rheumatoid arthritis receiving concomitant methotrexate therapy: a
randomized, placebo-controlled, 52-week trial. Arthritis Rheum,
50:1400-11.Therapeutics and Clinical Risk Management 2006:2(4) 399
Infliximab in the treatment of psoriatic arthritis
Korman NJ, Moul DK. 2005. Alefacept for the treatment of psoriasis: a
review of the current literature and practical suggestions for everyday
clinical use. Semin Cutan Med Surg, 24:10-8.
Lacey DL, Timms E, Tan HL, et al. 1998. Osteoprotegerin ligand is a
cytokine that regulates osteoclast differentiation and activation. Cell,
93:165-76.
Langevitz P, Buskila D, Gladman DD. 1990. Psoriatic arthritis precipitated
by physical trauma. J Rheumatol, 17:695-7.
Lebwohl M, Ting PT, Koo JY. 2005. Psoriasis treatment: traditional therapy.
Ann Rheum Dis, 64 (Suppl 2):ii83-6.
Lebwohl M, Tyring SK, Hamilton TK, et al. 2003. A novel targeted T-cell
modulator, efalizumab, for plaque psoriasis. N Engl J Med, 349:2004-
13.
Leonard DG, O’Duffy JD, Rogers RS. 1978. Prospective analysis of
psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin
Proc, 53:511-18.
Mader R, Gladman DD, Long J, et al. 1995. Does injectable gold retard
radiologic evidence of joint damage in psoriatic arthritis? Clin Invest
Med, 18:139-43.
Marguerie L, Flipo RM, Grardel B, et al. 2002. Use of disease-modifying
antirheumatic drugs in patients with psoriatic arthritis. Joint Bone
Spine, 69:275-81.
Mease P. 2003. Psoriatic arthritis/psoriasis. In: Smolen JS (ed). Targeted
Therapies in Rheumatology. London: Martin Dunitz Ltd. p 525-48.
Mease P. 2004a. Efalizumab in psoriatic arthritis. Toronto, Canada:
International Psoriasis Society.
Mease P. 2004b. TNFalpha therapy in psoriatic arthritis and psoriasis.
Ann Rheum Dis, 63:755-8.
Mease P, Gladman D, Keystone E. 2005. Efficacy of alefacept in
combination with methotrexate in the treatment of psoriatic arthritis.
Ann Rheum Dis, 64:324.
Mease P, Goffe BS. 2005. Diagnosis and treatment of psoriatic arthritis. J
Am Acad Dermatol, 52:1-19.
Mease PJ, Antoni CE. 2005. Psoriatic arthritis treatment: biological
response modifiers. Ann Rheum Dis, 64(Suppl 2):ii78-82.
Mease PJ, Gladman DD, Keystone EC. 2006. Alefacept in combination
with methotrexate for the treatment of psoriatic arthritis: results of a
randomized, double-blind, placebo-controlled study. Arthritis Rheum,
54: 1638-45.
Mease PJ, Gladman DD, Ritchlin CT, et al. 2005. Adalimumab for the
treatment of patients with moderately to severely active psoriatic
arthritis: results of a double-blind, randomized, placebo-controlled
trial. Arthritis Rheum, 52:3279-89.
Mease PJ, Goffe BS, Metz J, et al. 2000. Etanercept in the treatment of
psoriatic arthritis and psoriasis: a randomised trial. Lancet, 356:385-
90.
Mease PJ, Kivitz AJ, Burch FX, et al. 2004. Etanercept treatment of
psoriatic arthritis: safety, efficacy, and effect on disease progression.
Arthritis Rheum, 50:2264-72.
Moll JM, Wright V. 1973a. Familial occurrence of psoriatic arthritis. Ann
Rheum Dis, 32:181-201.
Moll JM, Wright V. 1973b. Psoriatic arthritis. Semin Arthritis Rheum, 3:55-
78.
Nakashima T, Wada T, Penninger JM. 2003. RANKL and RANK as novel
therapeutic targets for arthritis. Curr Opin Rheumatol, 15:280-7.
Nash P, Clegg DO. 2005. Psoriatic arthritis therapy: NSAIDs and traditional
DMARDs. Ann Rheum Dis, 64(Suppl 2):ii74-7.
Ory PA. 2003. Radiography in the assessment of musculoskeletal
conditions. Best Pract Res Clin Rheumatol, 17:495-512.
Ory PA, Gladman DD, Mease PJ. 2005. Psoriatic arthritis and imaging.
Ann Rheum Dis, 64(Suppl 2):ii55-7.
Pipitone N, Kingsley GH, Manzo A, et al. 2003. Current concepts and
new developments in the treatment of psoriatic arthritis. Rheumatology
(Oxford), 42:1138-48.
Rahman P, Bartlett S, Siannis F, et al. 2003. CARD15: a pleiotropic
autoimmune gene that confers susceptibility to psoriatic arthritis. Am
J Hum Genet, 73:677-81.
Rahman P, Gladman DD, Cook RJ, et al. 1998. The use of sulfasalazine
in psoriatic arthritis: a clinic experience. J Rheumatol, 25:1957-
61.
Reich K, Nestle FO, Papp K, et al. 2005. Infliximab induction and
maintenance therapy for moderate-to-severe psoriasis: a phase III,
multicentre, double-blind trial. Lancet, 366:1367-74.
Reich K, Nestle FO, Papp K, et al. 2006. Improvement in quality of life
with infliximab induction and maintenance therapy in patients with
moderate-to-severe psoriasis: a randomized controlled trial. Br J
Dermatol, 154:1161-8.
Remicade. 2006a. Remicade package insert, EU. Malvern, PA: Centocor,
Inc.
Remicade. 2006b. Remicade package insert, US. Malvern, PA: Centocor,
Inc.
Ritchlin C, Anandarajaha A, Totterman S, et al. 2004. Preliminary data
from a study of adalimumab in the treatment of psoriatic arthritis
[abstract]. Ann Rheum Dis, 63:403.
Ritchlin C, Haas-Smith SA, Hicks D, et al. 1998. Patterns of cytokine
production in psoriatic synovium. J Rheumatol, 25:1544-52.
Ritchlin CT, Haas-Smith SA, Li P, et al. 2003. Mechanisms of TNF-alpha-
and RANKL-mediated osteoclastogenesis and bone resorption in
psoriatic arthritis. J Clin Invest, 111:821-31.
Saklatvala J. 1986. Tumour necrosis factor alpha stimulates resorption and
inhibits synthesis of proteoglycan in cartilage. Nature, 322:547-9.
Salonen S. 2003. The EUROPSO psoriasis patient study: treatment history
and satisfaction reported by 17,900 members of European psoriasis
patients associations (poster).
Shbeeb M, Uramoto KM, Gibson LE, et al. 2000. The epidemiology of
psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J
Rheumatol, 27:1247-50.
Soderlin MK, Borjesson O, Kautiainen H, et al. 2002. Annual incidence
of inflammatory joint diseases in a population based study in southern
Sweden. Ann Rheum Dis, 61:911-15.
Sokoll KB, Helliwell PS. 2001. Comparison of disability and quality of
life in rheumatoid and psoriatic arthritis. J Rheumatol, 28:1842-6.
Swanbeck G, Inerot A, Martinsson T, et al. 1997. Genetic counselling in
psoriasis: empirical data on psoriasis among first-degree relatives of
3095 psoriatic probands. Br J Dermatol, 137:939-42.
Taylor W. 2006. ClASsification criteria for Psoriatic ARthritis: results from
the CASPAR study. Arthritis Rheum, 54:2665-73.
Terajima S, Higaki M, Igarashi Y, et al. 1998. An important role of tumor
necrosis factor-alpha in the induction of adhesion molecules in
psoriasis. Arch Dermatol Res, 290:246-52.
Van den Bosch F, Kruithof E, Baeten D, et al. 2000. Effects of a loading
dose regimen of three infusions of chimeric monoclonal antibody to
tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an
open pilot study. Ann Rheum Dis, 59:428-33.
Van der Heijde D, Gladman D, Kavanaugh A, et al. 2005. Infliximab
inhibits progression of radiographic damage in patients with active
psoriatic arthritis: 54 week results from IMPACT 2. Arthritis Rheum,
52:S281.
Veale D, Rogers S, Fitzgerald O. 1995. Immunolocalization of adhesion
molecules in psoriatic arthritis, psoriatic and normal skin. Br J
Dermatol, 132:32-8.
Veale D, Yanni G, Rogers S, et al. 1993. Reduced synovial membrane
macrophage numbers, ELAM-1 expression, and lining layer
hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis.
Arthritis Rheum, 36:893-900.
Veale DJ, Ritchlin C, FitzGerald O. 2005. Immunopathology of psoriasis
and psoriatic arthritis. Ann Rheum Dis, 64(Suppl 2):ii26-9.
Wassenberg S, Fischer-Kahle V, Herborn G, et al. 2001. A method to score
radiographic change in psoriatic arthritis. Z Rheumatol, 60:156-66.
Wick MC, Ernestam S, Lindblad S, et al. 2005. Adalimumab (Humira)
restores clinical response in patients with secondary loss of efficacy
from infliximab (Remicade) or etanercept (Enbrel): results from the
STURE registry at Karolinska University Hospital. Scand J
Rheumatol, 34:353-8.Therapeutics and Clinical Risk Management 2006:2(4) 400
Mease
Wong K, Gladman DD, Husted J, et al. 1997. Mortality studies in psoriatic
arthritis: results from a single outpatient clinic. I. Causes and risk of
death. Arthritis Rheum, 40:1868-72.
Wright V. 1959. Rheumatism and psoriasis: a re-evaluation. Am J Med,
27:454-62.
Zachariae H. 2003. Prevalence of joint disease in patients with psoriasis:
implications for therapy. Am J Clin Dermatol, 4:441-7.